Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event - Weinstock-Guttman, Bianca; Zivadinov, Robert; Horakova, Dana; Havrdova, Eva; Qu, Jun; Shyh, Grace; Lakota, Elizabeth; O'Connor, Kerri; Badgett, Darlene; Tamaño-Blanco, Miriam; Tyblova, Michaela; Hussein, Sara; et al. (Journal of neurology, neurosurgery and psychiatry, 2013)
Keywords: Adjuvants, Immunologic - therapeutic use; Adult; Body Mass Index; Brain - drug effects; Brain - pathology; Calcifediol - blood; Cholesterol - blood; Cholesterol, HDL - blood; Cholesterol, LDL - blood; Clinical Neurology; Cohort Studies; Czech Republic; Demyelinating Diseases - blood; Demyelinating Diseases - drug therapy; Early Medical Intervention; Female; Humans; Injections, Intramuscular; Interferon beta-1a; Interferon-beta - therapeutic use; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Mri; Multiple Sclerosis; Multiple Sclerosis - blood; Multiple Sclerosis - diagnosis; Multiple Sclerosis - drug therapy; Neurobiology; Neuroradiology; Prospective Studies; Smoking - adverse effects; Smoking - blood; Thyrotropin - blood; Thyroxine - blood; Young Adult; Czech Republic; Multiple Sclerosis; Clinical Neurology; Mri; Neuroradiology; Neurobiology